| Literature DB >> 27023506 |
Muhammad Nisar1, Shujaat Ali Khan2, Mughal Qayum3, Ajmal Khan4, Umar Farooq5, Hawa Z E Jaafar6, Muhammad Zia-Ul-Haq7, Rashid Ali8.
Abstract
The fluoroquinolone antibacterial drug ciprofloxacin (cip) has been used to cap metallic (silver and gold) nanoparticles by a robust one pot synthetic method under optimized conditions, using NaBH₄ as a mild reducing agent. Metallic nanoparticles (MNPs) showed constancy against variations in pH, table salt (NaCl) solution, and heat. Capping with metal ions (Ag/Au-cip) has significant implications for the solubility, pharmacokinetics and bioavailability of fluoroquinolone molecules. The metallic nanoparticles were characterized by several techniques such as ultraviolet visible spectroscopy (UV), atomic force microscopy (AFM), Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM) and energy dispersive X-ray (EDX) methods. The nanoparticles synthesized using silver and gold were subjected to energy dispersive X-ray tests in order to show their metallic composition. The NH moiety of the piperazine group capped the Ag/Au surfaces, as revealed by spectroscopic studies. The synthesized nanoparticles were also assessed for urease inhibition potential. Fascinatingly, both Ag-cip and Au-cip NPs exhibited significant urease enzyme inhibitory potential, with IC50 = 1.181 ± 0.02 µg/mL and 52.55 ± 2.3 µg/mL, compared to ciprofloxacin (IC50 = 82.95 ± 1.62 µg/mL). MNPs also exhibited significant antibacterial activity against selected bacterial strains.Entities:
Keywords: antibacterial activity; ciprofloxacin; metallic nanoparticles; urease enzyme inhibition
Mesh:
Substances:
Year: 2016 PMID: 27023506 PMCID: PMC6274037 DOI: 10.3390/molecules21040411
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Stabilizing and capping action of ciprofloxacin with noble metals (Ag/Au).
Figure 2(a) Optimized UV-Vis spectra of Ag-cip NPs (Inset: Ag-cip NP color); (b) Optimized UV-Vis spectra of Au-cip NPs (Inset: Au-cip NP color); (c) Effect of salt on the stability of Ag-cip NPs; (d) Effect of brine on the stability of Au-cip NPs; (e) Effect of pH on the stability of Ag-cip; (f) pH effect on the stability of Au-cip; (g) Effect of temperature on the stability of Ag-cip NPs. (Inset: effect of temperature on Ag-cip NP color; (h) temperature effect on the stability of Au-cip NPs. (Inset: effect of temperature on Au-cip NP color).
Figure 3(a) FTIR spectra of Ag-cip NPs; (b) FTIR spectra of Au-cip NPs; (c) AFM image of silver nanoparticles; (d) AFM image of gold nanoparticles.
Figure 4(a) EDX spectrum of Ag-cip NPs; (b) EDX spectrum of Au-cip NPs; (c) SEM image of Ag-cip NPs; (d) SEM image of Au-cip NPs.
Urease enzymes inhibition studies of Ag, ciprofloxacin, and ciprofloxacin-capped Ag/Au nanoparticles.
| Sample | Ag | Ciprofloxacin | Ag-Cip NPs | Au-Cip NPs | STD |
|---|---|---|---|---|---|
| % Inhibition | 29.2 | 75 | 96 | 90 | 98.2 |
| Concentration (mg/mL) | 0.2 | 0.2 | 0.2 | 0.2 | 0.5 (mM) |
| IC50 ± S.E.M (μg/mL) | NA | 82.95 ± 1.62 | 1.181 ± 0.02 | 52.55 ± 2.3 | 21 ± 0.11 (µM) |
S.E.M = Standard error mean; STD = Standard; Cip = ciprofloxacin.
Antibacterial activities of ciprofloxacin and its metallic (Ag/Au) nanoparticles (zone of inhibition (mm) at 3 mg/mL).
| Bacterial Strain | Strain | Ciprofloxacin | Ag-Cip NPs | Au-Cip NPs | Streptomycin (STD) |
|---|---|---|---|---|---|
|
| + | 26 | 24 | 22 | 26 |
|
| + | 28 | 22 | 24 | 26 |
|
| - | 24 | 20 | 24 | 28 |
Well size = 6 mm, STD = Standard.